Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα

  • US 7,541,031 B2
  • Filed: 04/17/2007
  • Issued: 06/02/2009
  • Est. Priority Date: 02/09/1996
  • Status: Expired due to Fees
First Claim
Patent Images

1. A method for treating a subject suffering from rheumatoid arthritis, comprising administering to the subject both an antibody and methotrexate, such that the rheumatoid arthritis is treated, wherein the antibody is an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNFα

  • with a Kd of 1×

    10

    8
    M or less and a Koff rate constant of 1×

    10

    3
    s

    1
    or less, both determined by surface plasmon resonance, neutralizes human TNFα

    cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×

    10

    7
    M or less, and neutralizes TNFα

    -induced cellular activation in a standard in vitro assay for TNRα

    -induced ELAM-1 expression on human umbilical vein endothelial cells (HUVEC).

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×